Cerus Corp.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US1570851014
USD
2.10
0.23 (12.3%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

1.53 M

Shareholding (Mar 2025)

FII

9.41%

Held by 71 FIIs

DII

57.04%

Held by 49 DIIs

Promoter

0.03%

How big is Cerus Corp.?

22-Jun-2025

As of Jun 18, Cerus Corp. has a market capitalization of 250.42 million, with net sales of 185.15 million and a net profit of -18.99 million over the last four quarters. Shareholder's funds total 56.15 million, and total assets are valued at 200.92 million.

As of Jun 18, Cerus Corp. has a market capitalization of 250.42 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the sum of net sales for the latest four quarters is 185.15 million, while the sum of net profit for the same period is -18.99 million.<BR><BR>As of Dec 24, the shareholder's funds amount to 56.15 million, and the total assets are valued at 200.92 million.

Read More

What does Cerus Corp. do?

22-Jun-2025

Cerus Corporation is a biomedical company focused on developing the INTERCEPT Blood System for blood safety. As of March 2025, it has net sales of $43 million, a market cap of $250.42 million, and is currently operating at a loss.

Overview:<BR>Cerus Corporation is a biomedical products company engaged in developing and commercializing the INTERCEPT Blood System for blood safety within the Pharmaceuticals & Biotechnology industry, categorized as a micro-cap company.<BR><BR>Financial Snapshot:<BR>- Most recent Net Sales: 43 Million (Quarterly Results - Mar 2025)<BR>- Most recent Net Profit: -8 Million (Quarterly Results - Mar 2025)<BR>- Market cap: USD 250.42 Million (Micro Cap)<BR><BR>Key Metrics:<BR>- P/E: NA (Loss Making)<BR>- Industry P/E: NA<BR>- Dividend Yield: 0.00%<BR>- Debt Equity: 0.12<BR>- Return on Equity: -34.22%<BR>- Price to Book: 4.51<BR><BR>Contact Details:<BR>- Address: 1220 Concord Ave Ste 600, CONCORD CA: 94520-4906<BR>- Tel: 1 925 2886000, 1 925 2886137<BR>- Fax: 1 925 2886001<BR>- Website: http://www.cerus.com/

Read More

Should I buy, sell or hold Cerus Corp.?

22-Jun-2025

Who are in the management team of Cerus Corp.?

22-Jun-2025

As of March 2022, the management team of Cerus Corp. includes Independent Chairman Mr. Daniel Swisher, President and CEO Mr. William Greenman, and several Independent Directors: Mr. Timothy Anderson, Mr. Eric Bjerkholt, Mr. Timothy Moore, Ms. Jami Nachtsheim, and Ms. Gail Schulze. They oversee the company's operations and strategic direction.

As of March 2022, the management team of Cerus Corp. includes the following individuals:<BR><BR>- Mr. Daniel Swisher, who serves as the Independent Chairman of the Board.<BR>- Mr. William Greenman, who is the President, Chief Executive Officer, and a Director.<BR>- Mr. Timothy Anderson, who is an Independent Director.<BR>- Mr. Eric Bjerkholt, who is also an Independent Director.<BR>- Mr. Timothy Moore, serving as an Independent Director.<BR>- Ms. Jami Nachtsheim, who is an Independent Director.<BR>- Ms. Gail Schulze, who is another Independent Director.<BR><BR>This team is responsible for overseeing the company's operations and strategic direction.

Read More

Is Cerus Corp. technically bullish or bearish?

20-Sep-2025

As of September 12, 2025, Cerus Corp. is in a bearish trend with weak strength signals, underperforming the S&P 500 significantly year-to-date and over the past year, indicating caution is advised.

As of 12 September 2025, the technical trend for Cerus Corp. has changed from mildly bearish to bearish. The current stance is bearish with weak strength indicated by the daily moving averages and the KST, both showing bearish signals. The weekly MACD is mildly bullish, but this is countered by the weekly Bollinger Bands being mildly bearish. The stock has underperformed significantly compared to the S&P 500 across multiple periods, with a year-to-date return of -15.58% versus the S&P 500's 12.22%, and a one-year return of -26.97% compared to 17.14% for the benchmark. Overall, the bearish indicators suggest caution in the current market environment.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
1

Poor long term growth as Operating profit has grown by an annual rate 9.20% of over the last 5 years

 
2

Positive results in Jun 25

3

Risky - Negative EBITDA

4

High Institutional Holdings at 83.59%

5

Consistent Underperformance against the benchmark over the last 3 years

stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 249 Million (Micro Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

0.17

stock-summary
Return on Equity

-34.15%

stock-summary
Price to Book

4.50

Revenue and Profits:
Net Sales:
52 Million
(Quarterly Results - Jun 2025)
Net Profit:
-6 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
60.31%
0%
60.31%
6 Months
45.83%
0%
45.83%
1 Year
18.64%
0%
18.64%
2 Years
25.75%
0%
25.75%
3 Years
-49.4%
0%
-49.4%
4 Years
-68.37%
0%
-68.37%
5 Years
-70.0%
0%
-70.0%

Cerus Corp. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
17.87%
EBIT Growth (5y)
9.20%
EBIT to Interest (avg)
-11.00
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
0.12
Sales to Capital Employed (avg)
1.24
Tax Ratio
1.09%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
83.59%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
5.20
EV to EBIT
-8.75
EV to EBITDA
-9.39
EV to Capital Employed
4.76
EV to Sales
1.59
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-54.34%
ROE (Latest)
-34.22%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
Bearish
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Bearish
Dow Theory
No Trend
Mildly Bullish
OBV
Mildly Bullish
Mildly Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 36 Schemes (33.52%)

Foreign Institutions

Held by 71 Foreign Institutions (9.41%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 16.19% vs 15.94% in Jun 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 1.72% vs 56.39% in Jun 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "52.40",
          "val2": "45.10",
          "chgp": "16.19%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-10.80",
          "val2": "-8.80",
          "chgp": "-22.73%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "2.10",
          "val2": "2.30",
          "chgp": "-8.70%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-5.70",
          "val2": "-5.80",
          "chgp": "1.72%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-211.80%",
          "val2": "-205.80%",
          "chgp": "-0.60%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 15.28% vs -3.46% in Dec 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 44.15% vs 12.15% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "180.30",
          "val2": "156.40",
          "chgp": "15.28%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-33.30",
          "val2": "-54.40",
          "chgp": "38.79%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "8.90",
          "val2": "8.40",
          "chgp": "5.95%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "-3.70",
          "chgp": "100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-21.00",
          "val2": "-37.60",
          "chgp": "44.15%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-195.70%",
          "val2": "-363.00%",
          "chgp": "16.73%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoYstock-summary
Jun'25
Jun'24
Change(%)
Net Sales
52.40
45.10
16.19%
Operating Profit (PBDIT) excl Other Income
-10.80
-8.80
-22.73%
Interest
2.10
2.30
-8.70%
Exceptional Items
0.00
0.00
Consolidate Net Profit
-5.70
-5.80
1.72%
Operating Profit Margin (Excl OI)
-211.80%
-205.80%
-0.60%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in quarter ended Jun 2025 is 16.19% vs 15.94% in Jun 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is 1.72% vs 56.39% in Jun 2024

Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
180.30
156.40
15.28%
Operating Profit (PBDIT) excl Other Income
-33.30
-54.40
38.79%
Interest
8.90
8.40
5.95%
Exceptional Items
0.00
-3.70
100.00%
Consolidate Net Profit
-21.00
-37.60
44.15%
Operating Profit Margin (Excl OI)
-195.70%
-363.00%
16.73%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is 15.28% vs -3.46% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 44.15% vs 12.15% in Dec 2023

stock-summaryCompany CV
About Cerus Corp. stock-summary
stock-summary
Cerus Corp.
Pharmaceuticals & Biotechnology
Cerus Corporation is a biomedical products company. The Company is engaged in developing and commercializing the INTERCEPT Blood System for blood safety. The Company operates through blood safety segment. The Company's INTERCEPT Blood System is based on its technology for controlling biological replication, and is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The Company's INTERCEPT Blood System is designed to target and inactivate blood-borne pathogens, such as viruses, including human immunodeficiency virus (HIV), West Nile, Severe acute respiratory syndrome (SARS), hepatitis B and C; bacteria and parasites, as well as harmful white blood cells, while preserving the therapeutic properties of platelet, plasma and red blood cell transfusion products. The Company's INTERCEPT Blood System is for use with blood components, including plasma, platelets, and red blood cells.
Company Coordinates stock-summary
Company Details
1220 Concord Ave Ste 600 , CONCORD CA : 94520-4906
stock-summary
Tel: 1 925 28860001 925 2886137
stock-summary
Registrar Details